What is the recommended dosing for Mirtazapine (Remeron)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirtazapine Dosing for Major Depressive Disorder

Start mirtazapine at 15 mg once daily at bedtime, and if inadequate response occurs, increase up to a maximum of 45 mg daily, with dose changes made no more frequently than every 1-2 weeks. 1

Initial Dosing

  • Begin with 15 mg once daily, administered orally in the evening prior to sleep 1
  • This starting dose is supported by both FDA labeling and clinical guidelines 2, 1
  • The bedtime administration takes advantage of mirtazapine's sedating properties, which can improve sleep disturbances often present in depression 2, 3

Dose Titration

  • If patients do not respond adequately to 15 mg, increase the dose up to a maximum of 45 mg per day 1
  • Wait at least 1-2 weeks between dose adjustments to allow sufficient time for evaluation of therapeutic response 1
  • The effective dosage range is 15-45 mg daily 3, 4
  • Some older literature mentions doses up to 80 mg/day, but the FDA-approved maximum is 45 mg daily 1, 5

Timeline for Response Assessment

  • Begin assessing therapeutic response and adverse effects within 1-2 weeks of treatment initiation 2
  • Mirtazapine has a faster onset of action than some SSRIs (fluoxetine, paroxetine, sertraline), with sleep and anxiety symptoms potentially improving within the first week 2, 3
  • If inadequate response occurs within 6-8 weeks, treatment modification is strongly recommended 2
  • Full antidepressant effect typically occurs within 2-4 weeks 3

Duration of Treatment

  • Continue treatment for 4-9 months after satisfactory response in patients with first-episode major depressive disorder 2
  • For patients with 2 or more depressive episodes, consider even longer duration of therapy 2

Dosage Modifications for Drug Interactions

Strong CYP3A Inducers

  • Increase mirtazapine dose when used concomitantly with strong CYP3A inducers (carbamazepine, phenytoin, rifampin) 1
  • Conversely, decrease dose if the inducer is discontinued 1

Strong CYP3A Inhibitors

  • Decrease mirtazapine dose when used with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) 1
  • Increase dose if the inhibitor is discontinued 1

Cimetidine

  • Decrease mirtazapine dose when used concomitantly with cimetidine 1
  • Increase dose if cimetidine is discontinued 1

Discontinuation

  • Gradually taper the dose rather than stopping abruptly to minimize withdrawal symptoms 1
  • Adverse reactions may occur upon abrupt discontinuation or rapid dose reduction 1

Special Populations

  • In patients with hepatic or renal impairment, use careful dose titration with regular monitoring 6
  • Mirtazapine is extensively metabolized by the liver and excreted mainly in urine, so clearance may be reduced in these populations 5

Important Clinical Considerations

  • Screen all patients for personal or family history of bipolar disorder, mania, or hypomania before initiating treatment 1
  • Allow at least 14 days between discontinuing an MAOI and starting mirtazapine, and vice versa 1
  • The elimination half-life of 20-40 hours supports once-daily dosing 3, 5

Common Side Effects to Monitor

  • Somnolence/sedation (often dose-related and may decrease at higher therapeutic doses) 2, 4
  • Increased appetite and weight gain 2, 4
  • Dry mouth 2, 4
  • Constipation or diarrhea 2

Clinical Advantages

  • Particularly suitable for patients with depression accompanied by insomnia or weight loss due to its sleep-promoting and appetite-stimulating properties 2
  • Minimal cardiovascular and anticholinergic effects compared to tricyclic antidepressants 3
  • Lacks serotonergic side effects such as gastrointestinal symptoms and sexual dysfunction common with SSRIs 3, 5

References

Guideline

Mirtazapine Treatment Guidelines for Major Depressive Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Mirtazapine, an antidepressant.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.